| Literature DB >> 29207552 |
Sudip Mondal1, Panchanathan Manivasagan2, Subramaniyan Bharathiraja3, Madhappan Santha Moorthy4, Van Tu Nguyen5, Hye Hyun Kim6, Seung Yun Nam7,8,9, Kang Dae Lee10, Junghwan Oh11,12,13.
Abstract
Targeting cancer cells without injuring normal cells is the prime objective in treatment of cancer. In this present study, solvothermal and wet chemical precipitation techniques were employed to synthesize iron oxide (IO), hydroxyapatite (HAp), and hydroxyapatite coated iron oxide (IO-HAp) nanoparticles for magnetic hyperthermia mediated cancer therapy. The synthesized well dispersed spherical IO-HAp nanoparticles, magnetite, and apatite phases were confirmed by X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FTIR) and Field emission transmission electron microscopy (FETEM) with Energy Dispersive X-ray spectroscopy (EDS). The non-toxic behavior of synthesized IO-HAp nanoparticles was confirmed by cytotoxicity assay (Trypan blue and MTT assay). The synthesized nanoparticles revealed a remarkable magnetic saturation of 83.2 emu/g for IO and 40.6 emu/g for IO-HAp nanoparticles in presence of 15,000 Oe (1.5 T) magnetic field at room temperature (300 K). The magnetic hyperthermia study that was performed with IO-HAp nanoparticles showed an excellent hyperthermia effect (SAR value 85 W/g) over MG-63 osteosarcoma cells. The in vitro hyperthermia temperature (~45 °C) was reached within 3 min, which shows a very high efficiency and kills nearly all of the experimental MG-63 osteosarcoma cells within 30 min exposure. These results could potentially open new perceptions for biomaterials that are aimed for anti-cancer therapies based on magnetic hyperthermia.Entities:
Keywords: cancer therapy; hydroxyapatite; hydroxyapatite coated iron oxide; iron oxide; magnetic hyperthermia
Year: 2017 PMID: 29207552 PMCID: PMC5746916 DOI: 10.3390/nano7120426
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Scheme 1Magnetic hydroxyapatite (IO-HAp) mediated hyperthermia study to treat cancer.
Figure 1Synthesis of hydroxyapatite coated iron oxide (IO-HAp) nanoparticles.
Figure 2X-ray diffraction (XRD) analysis of (a) IO, (b) HAp and (c) comparing HAp, IO-HAp, and IO nanoparticles.
Figure 3(a) FTIR and (b) Thermogravimetric analysis of IO, HAp and IO-HAp nanoparticles.
Fourier-transform infrared spectroscopy (FTIR) spectra analysis of HAp, IO and IO-HAp nanoparticles.
| Sl. No. | Wavenumber cm−1 | Functional Groups | Reference | ||
|---|---|---|---|---|---|
| HAp | IO | IO-HAp | |||
| 1 | 3450–3575 | 3450–3575 | 3450–3575 | O–H group stretching vibration | [ |
| 2 | 462–479 | 479 | 462 | [ | |
| 3 | 1646 | -- | 1641 | O–H adsorbed water | [ |
| 4 | 1452 | -- | 1448 | C–O stretching vibration | [ |
| 5 | -- | 1060 | -- | weak vibration of Fe–OH group | [ |
| 6 | 1098–1046 | -- | 1046 | [ | |
| 7 | 883 | -- | 883 | [ | |
| 8 | 634 | -- | 634 | libration mode of the O–H | [ |
| 9 | 605 | -- | 605 | [ | |
| 10 | 567 | -- | 567 | [ | |
| 11 | -- | 570 | -- | Fe–O vibrations for IO | [ |
| 12 | -- | 2920 | 2920 | C–H vibration | [ |
Figure 4Field emission transmission electron microscopy (FETEM) analysis of (a) IO (inset particle size distribution) (b) dynamic light scattering (DLS) particle size distribution of IO nanoparticles, (c) and (d) FETEM analysis of IO-HAp nanoparticles (e) DLS particle size distribution of IO-HAp nanoparticles (f) EDS analysis of IO-HAp nanoparticles.
Figure 5Magnetization curve of IO and IO-HAp nanoparticles (inset corresponds to a low-field region of IO and IO-HAp nanoparticles magnetic saturation curve to identify the coercivity and remanent magnetization).
Different synthetic routes application and their corresponding saturation magnetization (Ms) value of magnetic hydroxyapatite nanoparticles.
| Sl. No. | Synthesis Route | Application | Saturation Magnetization (Ms) | Reference |
|---|---|---|---|---|
| 1 | Wet precipitation technique | Biomedicine application, Hyperthermia study. | 7.23–20.92 emu/g | [ |
| 2 | Pulsed plasma deposition | Biofilm formation | 0.26 emu/g | [ |
| 3 | Hydrothermal method | Biomedicine applications | ~0.32 emu/g | [ |
| 4 | Spray-drying technique | Medical diagnosis and imaging | ~12 emu/g | [ |
| 5 | Microwave route | pH-responsive drug release | 18.9 emu/g | [ |
| 6 | Multi step synthesis: wet precipitation, hydrothermal, ultrasonication, and layer by layer coating | Magnetic resonance imaging, Drug delivery | ~4–7 emu/g | [ |
| 7 | Hydrothermal method | pH dependent protein adsorption release carrier | 11.5–15.5 emu/g | [ |
| 8 | Polymer templated electrospun technique | Biomedical and hyperthermia treatment | 27.20 emu/g | [ |
| 9 | Ultrasonic irradiation technique | Biomedical | 7.40 emu/g | [ |
| 10 | Chemical precipitation | Magnetic hyperthermia for cancer treatment | 40.6 emu/g | Present Study |
Figure 6Cell viability study of MG-63 cells (a) incubated with different concentration HAp, IO, and IO-HAp nanoparticles for 24 h and (b) incubated (100 g/mL) nanoparticles with different time period (24, 48 and 72 h).
Figure 7Trypan blue cell viability study of MG-63 cells incubated (a) without any nanoparticles as control (b) HAp, (c) IO, and (d) IO-HAp nanoparticles for 24 h with a concentration of 100 µg/mL.
Figure 8Magnetic hyperthermia study of (a) IO and HAp coated IO (IO-HAp) (b) hyperthermia study of IO-HAp and their corresponding infrared thermal images (c) hyperthermia and cell death mechanism.